Can Melatonin Actually Relieve Chronic Musculoskeletal Pain? What the Latest Review Shows

How Does Melatonin Compare to Standard Pain Medications?

The table below summarises the key comparison points drawn from the PAIN meta-analysis and supporting clinical literature. All pain reduction figures use a 0–100 numeric rating scale unless otherwise noted.

Feature	Melatonin (3–10 mg)	NSAIDs (e.g., ibuprofen)	Opioids (low-dose)
Mean pain reduction (0–100 scale)	~9–10 points	~10–12 points (typical RCT range)	~10–12 points (typical RCT range)
Sleep quality improvement	Yes — favours melatonin in chronic MSK pain	No direct benefit	May worsen sleep architecture
Dependence / addiction risk	No evidence of dependence	No physical dependence	High dependence risk
Serious adverse events in trials	None recorded	GI bleeding, cardiovascular risk	Respiratory depression, overdose
Common mild side effects	Nausea, dizziness, headache (similar to placebo rates)	GI upset, headache	Nausea, constipation, sedation
Typical cost per dose (Australia)	Often < AUD $1.50 per tablet	Low–moderate	Moderate–high (plus monitoring costs)
Regulatory status (EU, as supplement)	Authorised for sleep/jet lag only; pain claims not permitted	OTC/prescription depending on dose	Prescription only
Evidence certainty (GRADE)	Low to moderate	Moderate to high	Moderate to high

Sources: PAIN meta-analysis; News Medical/University of Sydney; Vitafoods Insights.

Melatonin's pain reduction numbers sit in the same neighbourhood as conventional analgesics, but the evidence base supporting those conventional drugs is considerably deeper. The real competitive advantage lies in the safety column: no serious adverse events, no dependence, and a side-effect profile indistinguishable from placebo in most trials.

What Exactly Did the 2026 PAIN Review Find?

The study, led by PhD student Kangchao Wu from the Musculoskeletal Research Hub at the Charles Perkins Centre and the School of Health Sciences at the University of Sydney, is a systematic review and meta-analysis of placebo-controlled and active-controlled randomised controlled trials (RCTs). It is the first review to evaluate both melatonin's efficacy (versus placebo) and effectiveness (versus active comparators such as analgesics) in the same analysis — a methodological gap that previous reviews had left open.

The researchers searched six databases from inception to April 2025, including the Cochrane Library, MEDLINE, and EMBASE. Twenty-three RCTs with a combined 2,028 participants were included. Participants came from the US, Russia, Brazil, Egypt, China, and other countries, carrying diagnoses spanning low back pain, osteoarthritis, fibromyalgia, and post-surgical pain from joint replacements and spinal procedures.

The headline results break down by population:

For chronic musculoskeletal pain, melatonin was not statistically superior to placebo in the primary analysis (mean difference: −6.76/100; 95% CI: −15.89 to 2.36), but outperformed active controls — meaning it beat existing analgesics — with a mean difference of −11.21/100 (95% CI: −14.29 to −8.13). In the sensitivity analysis restricted to low-risk-of-bias studies, melatonin was superior to placebo (MD: −10.04; 95% CI: −17.68 to −2.39). Sleep quality also favoured melatonin in this group.

For postoperative musculoskeletal pain, melatonin was superior to placebo, with effects similar to active controls. Sleep quality did not show a significant benefit in this subgroup.

Adverse events were mild and transient across the board. The most commonly reported side effects — nausea, dizziness, and headaches — occurred at rates similar to the placebo group, and no serious adverse events were recorded.

The authors registered the review prospectively on PROSPERO (ID: CRD42023495805) and followed PRISMA reporting standards.

Why Would a Sleep Hormone Affect Pain at All?

Melatonin's roles extend well beyond circadian rhythm regulation. Animal studies conducted over several decades suggest it may have analgesic properties mediated through multiple neurotransmitter pathways, including opioidergic, GABAergic, and serotonergic systems. In peripheral tissues relevant to musculoskeletal pain, melatonin receptors (MT1 and MT2) appear to modulate inflammatory cytokine signalling — specifically interleukin-1β, interleukin-6, and tumour necrosis factor-alpha, all of which promote central sensitisation.

The pain-sleep relationship is bidirectional and well-documented. Pain disrupts sleep by activating stress responses and making it harder to fall and stay asleep. Disrupted sleep, in turn, heightens pain severity and pain sensitivity by increasing pro-inflammatory cytokines and disrupting central pain inhibitory mechanisms. A meta-analysis cited in the review found pooled prevalence of sleep disturbances in chronic non-cancer pain as high as 75.9%.

This creates a vicious cycle that melatonin may interrupt at two points simultaneously: by improving sleep architecture and by direct analgesic action on pain-modulating systems.

Dr Bart Morlion, former president of the European Pain Federation (EFIC) and director of the Leuven Centre for Algology and Pain Management, frames it carefully. He does not believe melatonin is a direct analgesic drug, but considers it "a very useful adjunctive therapy in sleep regulation in chronic pain, because sleep is one of the first things which is disturbed in patients with chronic pain." He adds: "Although it has no direct pain-reducing effect, improving sleep can lead to improved pain scores during the day."

That framing — sleep improvement as the primary mechanism, with downstream pain relief as the benefit — matters for both clinical communication and regulatory compliance.

What Doses Were Used, and Is There an Optimal Amount?

Dosing across the 23 trials was heterogeneous, which is one reason the authors call for standardised protocols in future research.

For chronic musculoskeletal pain, doses typically ranged from 3 to 10 mg per day, with 3 mg the most commonly used. For postoperative pain, doses ranged from 1 to 10 mg, with 5 to 6 mg most frequently used. In both settings, melatonin was generally taken at bedtime or up to one hour before sleep.

The researchers found no clear dose-response relationship — meaning the current evidence does not support recommending a single optimal dose. Higher doses did not consistently produce greater pain relief, which is consistent with melatonin's known pharmacology: the hormone operates via receptor saturation at relatively low concentrations, and supraphysiological doses may not translate to proportionally greater effects.

The DREAM–CP randomised controlled trial, a separate double-blind crossover study from the University of Aberdeen published in the British Journal of Anaesthesia, tested 2 mg of modified-release melatonin (Circadin™) in 60 patients with severe chronic non-cancer pain. It found consistent but transient improvements in sleep disturbance, latency, and overall sleep quality at three weeks, though these did not persist to the six-week primary endpoint. Pain intensity scores improved during both treatment periods — including placebo — suggesting a meaningful placebo effect in this population. The trial's authors concluded that melatonin "holds promise for individual chronic pain patients with flare-up episodes or in need of respite."

The transience of the DREAM–CP findings is a useful counterweight to the more optimistic headline numbers from the Sydney meta-analysis. Both sets of results point to real but modest, time-limited benefits — not a cure.

How Safe Is Melatonin for People With Chronic Pain?

The safety profile is one of melatonin's most compelling attributes relative to conventional analgesics. Across the 23 trials in the PAIN meta-analysis, adverse events were mild and transient, with no serious adverse events recorded. The most commonly reported side effects — nausea, dizziness, and headaches — occurred at rates comparable to placebo, a strong indicator that these events are not causally related to melatonin.

Existing literature confirms that high-dose or long-term use does not lead to drug dependence or serious adverse events. Melatonin is generally considered safe for short-term use of less than three months. This matters enormously in chronic pain management, where long-term opioid use carries risks of dependence, tolerance, overdose, and hormonal disruption, and where long-term NSAID use raises cardiovascular and gastrointestinal risks.

Dr Morlion adds a nuance worth noting: some of his patients report difficulty stopping melatonin, though not to the degree seen with classical hypnotic drugs like benzodiazepines or Z-drugs. At high doses — 5 to 10 mg taken for six months — some patients report immediate sleep problems if they stop abruptly. This is not pharmacological dependence in the classical sense, but it is a practical consideration for prescribers and patients planning to discontinue.

Lead author Kangchao Wu is direct about the risk-benefit calculation: "Melatonin is already in people's homes, it's inexpensive, and we know it's safe. Our advice isn't for melatonin to replace every pain medication. Instead, after consultation with a doctor, it may be used as an adjunct to existing treatments, particularly for people who also experience sleep problems."

Patients taking other medications or managing underlying health conditions should discuss melatonin with their doctor before starting, given potential interactions — particularly with anticoagulants, immunosuppressants, and other CNS-active agents.

Does Melatonin Work for Specific Conditions Like Fibromyalgia or Osteoarthritis?

The 23 trials in the PAIN meta-analysis covered a range of musculoskeletal diagnoses, including low back pain, osteoarthritis, fibromyalgia, and post-surgical recovery from joint replacements and spinal procedures. The review did not report condition-specific effect sizes in the available abstract and summary data — a genuine limitation, since melatonin's benefits may be concentrated in certain diagnoses rather than uniformly distributed across all musculoskeletal pain types.

The DREAM–CP trial, which focused on severe chronic non-cancer pain as a heterogeneous category, found sleep improvements at three weeks but not six, and did not isolate fibromyalgia or osteoarthritis as separate subgroups. An earlier 2020 systematic review of 30 trials (n = 1,967) covering all pain types — cited in the PAIN review's introduction — concluded that melatonin might be effective for chronic pain but not for acute postoperative pain. The 2026 review partially challenges this, finding postoperative benefits as well, though the evidence in that subgroup is more limited.

For fibromyalgia specifically, the DREAM–CP authors note that melatonin has been shown to improve fibromyalgia symptoms in prior research, which aligns with the known overlap between fibromyalgia, disrupted sleep, and central sensitisation — all areas where melatonin's mechanisms are plausibly relevant.

The honest answer is that condition-specific evidence is thin. Patients with fibromyalgia who also have significant sleep disruption may be the most likely to benefit, given the dual mechanism. Those with purely nociceptive pain and intact sleep may see less.

What Do Regulatory Rules Mean for Melatonin Pain Products?

This is where the science and the market diverge sharply. The clinical evidence is building, but the regulatory framework in major markets does not yet accommodate melatonin pain claims — and that gap has direct implications for supplement manufacturers.

In the European Union, the regulatory space is defined by dosage thresholds that vary by member state. In the Netherlands, melatonin products below 0.3 mg are classified as food supplements; in Finland, the threshold is 2 mg. Products above those thresholds are classified as medicines. The only two health claims authorised in the EU for melatonin sold as a food supplement are: (1) it contributes to the reduction of time taken to fall asleep, and (2) it contributes to the alleviation of subjective feelings of jet lag.

Any reference to pain management — even indirect — would constitute a medical claim, prohibited for food supplements under EU regulations. Mari Lyyra, regulatory affairs manager at Finnish consultancy Medfiles, is unambiguous: "A food supplement marketer must not suggest, even indirectly, that the product is intended for uses other than those that may legally be communicated for the product." If a melatonin product were marketed for pain relief, it would automatically be classified as a medicine regardless of dose, requiring full medicinal authorisation.

In Australia, melatonin is not available as a standard over-the-counter supplement. Most products require a prescription, although low-dose melatonin (2 mg or less) can be supplied by a pharmacist without a prescription for short-term insomnia treatment in adults aged 55 and older. Pain indications are not covered.

For manufacturers, the practical implication is that the same product cannot be marketed for both sleep and pain management. The science may support a dual benefit, but the regulatory pathway for a pain claim runs through the medicines approval process — a considerably higher bar than food supplement registration.

Dr Morlion's framing offers a compliant communication route: "Improving sleep can lead to improved pain scores during the day. That's not telling patients or consumers that melatonin is an analgesic drug. That would be a claim which you cannot make." Communicating the sleep-pain link through the sleep benefit — rather than making a direct pain claim — may be the only legally viable approach for supplement marketers in the near term.

What Are the Limitations of the Current Evidence?

The PAIN meta-analysis is the most comprehensive review of melatonin for musculoskeletal pain to date, but its authors are candid about the evidence gaps.

Certainty of evidence is low to moderate. Under the GRADE framework, this means the true effect could differ meaningfully from the estimated effect — a rating that reflects heterogeneity across trials, variable risk of bias, and inconsistency in dosing protocols.

No dose-response relationship was identified. Without knowing which dose produces the best outcomes, clinicians cannot give precise guidance, and researchers cannot design optimally powered follow-up trials.

Most effect estimates did not reach the minimal clinically important difference (MCID) in every analysis. A 9–10 point reduction on a 100-point scale is statistically significant and clinically meaningful in context, but the MCID for pain scales is typically cited at 10–15 points depending on the condition. Some analyses fell below this threshold.

Follow-up periods were short. Chronic pain is a long-term condition; most trials ran for weeks to a few months. Whether melatonin's benefits persist over one, two, or five years is unknown.

Standardised dosing protocols are absent. The heterogeneity in dose, formulation (immediate-release vs. modified-release), and timing across trials makes it difficult to pool results cleanly or translate findings directly into clinical practice.

The primary analysis versus placebo was not statistically significant for chronic MSK pain, though the sensitivity analysis restricted to low-risk studies was. The full dataset includes trials with higher risk of bias that may dilute the true effect — but it also means the headline result depends on which analytical lens you apply.

The researchers call explicitly for large-scale RCTs with standardised dosing protocols and longer follow-up periods before melatonin can be recommended with high confidence as a chronic pain adjunct.

Should Patients With Chronic Musculoskeletal Pain Consider Melatonin?

The evidence supports cautious, doctor-supervised use as an adjunct — not a replacement — for patients who have both chronic musculoskeletal pain and sleep disruption. That combination is extremely common: sleep disturbances affect up to 75.9% of people with chronic non-cancer pain, making the overlap the rule rather than the exception.

The case for melatonin is strongest when the patient already experiences significant sleep disruption alongside their pain; when conventional analgesics are being used at doses that raise long-term safety concerns; when a low-cost, low-risk adjunct that could reduce reliance on opioids or high-dose NSAIDs is the goal; or when short-term use under three months is planned, with reassessment thereafter.

The case is weaker when pain is purely nociceptive with no sleep component, when the patient expects melatonin to replace existing pain management, or when long-term use at high doses (5–10 mg) is planned without medical supervision.

Prof Paulo Ferreira, director of the Musculoskeletal Research Hub and co-author of the PAIN review, captures the broader significance: "We're taking a medication we already understand and applying it to a problem that affects a huge proportion of the global population." The drug-repurposing angle is real — melatonin's safety profile, cost, and accessibility are already established. What remains is the clinical infrastructure to deploy it appropriately.

For patients managing conditions like osteoarthritis or low back pain — conditions also discussed in our guide on natural supplements for knee arthritis pain — melatonin represents one piece of a broader evidence-based toolkit rather than a standalone solution.

The global melatonin market is projected to grow over the next five years, driven by rising interest in sleep supplements and increasing prevalence of sleep deficiency and stress, according to Mordor Intelligence. Whether pain management becomes a formal driver of that growth depends on regulatory evolution — and on whether the next generation of large, well-designed RCTs can push the GRADE certainty rating from "low to moderate" to "high."

The honest summary is this: melatonin probably helps with chronic musculoskeletal pain, particularly by improving sleep and thereby breaking the pain-sleep cycle. The effect size is clinically meaningful and comparable to common analgesics. The safety profile is genuinely favourable. The evidence is not yet strong enough to change clinical guidelines, but it is strong enough to support an informed conversation between patient and clinician.